CD274 and gastric neoplasm: The newest developments in precision oncology have spurred the combination of chemotherapy, targeted therapy, and immunotherapy to enhance outcome in a small subset of patients with PD-L1-positive or MSI-H gastric tumors (5); but again, their activity is significantly less in tumors with PD-L1 negativity and microsatellite stability (MSS) aka immune cold tumors (6, 7).